<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Clinical manifestations and evaluation of hyperprolactinemia</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Clinical manifestations and evaluation of hyperprolactinemia</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Clinical manifestations and evaluation of hyperprolactinemia</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Peter J Snyder, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David S Cooper, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kathryn A Martin, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 16, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The clinical manifestations of hyperprolactinemia are relatively few and usually easy to recognize. Once hyperprolactinemia excess is identified, further evaluation to establish the underlying cause is usually straightforward. The clinical manifestations and evaluation of hyperprolactinemia are reviewed here. The causes and treatment of hyperprolactinemia are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/6626.html" rel="external">"Causes of hyperprolactinemia"</a> and  <a class="medical medical_review" href="/z/d/html/6630.html" rel="external">"Management of hyperprolactinemia"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">CLINICAL PRESENTATION</span><span class="headingEndMark"> — </span>Hyperprolactinemia causes typical symptoms in premenopausal females and in males, but not in postmenopausal females.</p><p class="headingAnchor" id="H3"><span class="h2">Premenopausal females</span><span class="headingEndMark"> — </span>Hyperprolactinemia in premenopausal females causes hypogonadism, with symptoms that include infertility, oligomenorrhea, or amenorrhea [<a href="#rid1">1,2</a>] and less often galactorrhea. In a retrospective study of 104 patients with hyperprolactinemia ages 30 to 44 years, the most commonly reported symptoms were infertility, headache, and oligomenorrhea in 48, 39, and 29 percent, respectively [<a href="#rid3">3</a>]. Galactorrhea was slightly less common (24 percent).</p><p class="headingAnchor" id="H4"><span class="h3">Menstrual cycle dysfunction</span><span class="headingEndMark"> — </span>Excluding pregnancy, hyperprolactinemia accounts for approximately 10 to 20 percent of cases of amenorrhea. The mechanism appears to involve inhibition of luteinizing hormone (LH), and perhaps follicle-stimulating hormone (FSH) secretion, via inhibition of the release of gonadotropin-releasing hormone (GnRH). As a result, serum gonadotropin concentrations are normal or low, as in other causes of secondary hypogonadism.</p><p>The symptoms of hypogonadism due to hyperprolactinemia in premenopausal females correlate with the magnitude of the hyperprolactinemia. In most laboratories, a serum prolactin concentration above 15 to 20 ng/mL (15 to 20 mcg/L SI units) is considered abnormally high in females of reproductive age.</p><p class="bulletIndent1"><span class="glyph">●</span>A serum prolactin concentration greater than 100 ng/mL (100 mcg/L SI units) is typically associated with overt hypogonadism, subnormal estradiol secretion, and its consequences, including amenorrhea, hot flashes, and vaginal dryness.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Moderate degrees of hyperprolactinemia, eg, serum prolactin values of 50 to 100 ng/mL (50 to 100 mcg/L SI units), cause either amenorrhea or oligomenorrhea.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Mild degrees of hyperprolactinemia, eg, serum prolactin values of 20 to 50 ng/mL (20 to 50 mcg/L SI units), may cause only insufficient progesterone secretion and, therefore, a short luteal phase of the menstrual cycle [<a href="#rid4">4,5</a>]. Mild hyperprolactinemia can cause infertility even when there is no abnormality of the menstrual cycle; these females account for approximately 20 percent of those evaluated for infertility.</p><p></p><p class="headingAnchor" id="H438374791"><span class="h3">Bone density</span><span class="headingEndMark"> — </span>Females with amenorrhea secondary to hyperprolactinemia have a lower spine and forearm bone mineral density compared with normal females or females with hyperprolactinemia and normal menses [<a href="#rid6">6,7</a>]. Restoration of menses following therapy results in an increase in bone density, although it may not return to normal [<a href="#rid6">6,7</a>]. Adolescents, when compared with adults with lactotroph adenomas, have lower bone density at the time of diagnosis and less improvement after two years of dopamine agonist therapy [<a href="#rid8">8</a>].</p><p class="headingAnchor" id="H5"><span class="h3">Galactorrhea</span><span class="headingEndMark"> — </span>Hyperprolactinemia in premenopausal females can also cause galactorrhea [<a href="#rid9">9</a>], but most premenopausal females who have hyperprolactinemia do not have galactorrhea (see <a class="local">'Premenopausal females'</a> above). Many females who have galactorrhea have normal serum prolactin concentrations [<a href="#rid9">9</a>]. (See <a class="local">'Galactorrhea without hyperprolactinemia'</a> below and  <a class="medical medical_review" href="/z/d/html/802.html" rel="external">"Nipple discharge"</a>.)</p><p class="headingAnchor" id="H6"><span class="h2">Postmenopausal females</span><span class="headingEndMark"> — </span>Postmenopausal females, by definition, are already hypogonadal, and hyperprolactinemia does not change that situation. Because postmenopausal females are also markedly hypoestrogenemic, galactorrhea is rare. Hyperprolactinemia in these females is recognized only in the relatively unusual situation when a lactotroph adenoma becomes so large as to cause headaches or impair vision or is detected as an incidental finding when a magnetic resonance imaging (MRI) study is performed for an unrelated reason.</p><p class="headingAnchor" id="H7"><span class="h2">Males</span><span class="headingEndMark"> — </span>Hyperprolactinemia in males also causes hypogonadotropic hypogonadism, which is manifested by decreased libido, infertility, gynecomastia, or, rarely, galactorrhea [<a href="#rid10">10,11</a>]. As in females, there is a rough correlation between the presence of any of these symptoms and the degree of hyperprolactinemia.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hypogonadotropic hypogonadism</strong> – Hyperprolactinemia causes decreased testosterone secretion and low serum testosterone concentrations that are not associated with an increase in LH secretion [<a href="#rid10">10</a>]. As in females, the effect of prolactin must be on the pituitary or hypothalamus. The consequences of the hypogonadism are similar to those of hypogonadism due to other causes and include, in the short term, decreased energy and libido, and in the long term, decreased muscle mass, decreased body hair, and osteoporosis. In one study of 20 males, for example, 16 had osteopenia in the spine and six in the hip [<a href="#rid12">12</a>]. (See  <a class="medical medical_review" href="/z/d/html/7460.html" rel="external">"Causes of secondary hypogonadism in males", section on 'Hyperprolactinemia'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Erectile dysfunction</strong> – Hyperprolactinemia appears to cause erectile dysfunction by a mechanism unrelated to hypogonadism, because correcting the hyperprolactinemia with a dopamine agonist corrects the impotence. One report suggests that correcting the hypogonadism by the administration of testosterone does not correct the impotence, which corresponds to the author's clinical observations [<a href="#rid10">10</a>]. (See  <a class="medical medical_review" href="/z/d/html/6840.html" rel="external">"Epidemiology and etiologies of male sexual dysfunction", section on 'Epidemiology'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Infertility</strong> – Although hyperprolactinemia can cause infertility in males, probably by decreasing LH and perhaps FSH secretion, it is not a common finding among males who present for evaluation of infertility. In a study of 171 infertile males, as an example, only seven (4 percent) had hyperprolactinemia [<a href="#rid11">11</a>]. (See  <a class="medical medical_review" href="/z/d/html/7473.html" rel="external">"Causes of male infertility", section on 'Endocrine and systemic disorders (hypogonadotropic hypogonadism)'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Galactorrhea</strong> – Males with hyperprolactinemia may develop galactorrhea. This occurs less often than in females, presumably because the glandular breast tissue in males has not been made sensitive to prolactin by preceding stimulation by estradiol and progesterone.</p><p></p><p class="headingAnchor" id="H125670483"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis of hyperprolactinemia is made by a serum prolactin concentration that is well above the normal range (&gt;20 ng/mL [20 mcg/L]) in males and postmenopausal females and &gt;30 ng/mL in premenopausal females. Because meals may stimulate prolactin secretion slightly, if an initial serum prolactin concentration is only slightly elevated (21 to 40 ng/mL [21 to 40 mcg/L SI units]), the test should be repeated on a fasting sample before the patient is considered to have hyperprolactinemia. (See <a class="local">'Evaluation of hyperprolactinemia'</a> below.)</p><p>Hyperprolactinemia is a potential cause of oligomenorrhea, amenorrhea, galactorrhea, and infertility in females and hypogonadism and/or erectile dysfunction in males. Therefore, serum prolactin should be measured in a patient who presents with any of these symptoms [<a href="#rid13">13</a>].</p><p class="headingAnchor" id="H125670444"><span class="h2">Serum prolactin concentrations</span><span class="headingEndMark"> — </span>The usual normal range for serum prolactin is approximately 5 to 20 ng/mL (5 to 20 mcg/L). The measurement can be performed at any time since usual daily activities have little effect on prolactin secretion. However, serum prolactin concentrations may increase slightly during sleep, strenuous exercise, and occasionally with emotional or physical stress, intense breast stimulation, and high-protein meals. Therefore, if an initial prolactin level is only borderline high, the test should be repeated (see <a class="local">'Evaluation of hyperprolactinemia'</a> below). Normal values are higher in females than males, and dynamic testing is not needed.</p><p class="headingAnchor" id="H529482178"><span class="h2">Pitfalls in diagnosis</span></p><p class="headingAnchor" id="H529482184"><span class="h3">Hook effect</span><span class="headingEndMark"> — </span>Immunoassays for prolactin that had been used in prior years commonly gave artefactually low values when the actual prolactin concentration was very high, eg, 5000 ng/mL (5000 mcg/L) [<a href="#rid14">14-16</a>]. This effect occurs when a very high serum prolactin, eg, 5000 ng/mL (5000 mcg/L SI units), saturates both the capture and signal antibodies used in immunoradiometric and chemiluminescent assays, preventing the binding of the two in a "sandwich." The result is an apparent prolactin concentration that is only modestly elevated, suggesting that the macroadenoma is clinically nonfunctioning. The artifact can be avoided by repeating the assay using a 1:100 dilution of serum [<a href="#rid13">13</a>]. Most commercially available prolactin assays used today are not subject to this artefact [<a href="#rid17">17</a>].</p><p class="headingAnchor" id="H529482190"><span class="h3">Macroprolactin</span><span class="headingEndMark"> — </span>Macroprolactin causes hyperprolactinemia through decreased prolactin clearance. Macroprolactin is native prolactin that is bound to immunoglobulin G (IgG) and is usually 150 to 170 kDa in size, compared with 23 kDa for monomeric prolactin [<a href="#rid18">18</a>]. This entity is not of clinical significance directly, but patients can be misdiagnosed and treated as ordinary hyperprolactinemia. Misdiagnosis can be avoided by asking the laboratory to pretreat the serum with polyethylene glycol to precipitate the macroprolactin before the immunoassay for prolactin in the supernatant. This entity is discussed in greater detail separately. (See  <a class="medical medical_review" href="/z/d/html/6626.html" rel="external">"Causes of hyperprolactinemia", section on 'Macroprolactinemia'</a>.)</p><p class="headingAnchor" id="H8"><span class="h1">EVALUATION OF HYPERPROLACTINEMIA</span><span class="headingEndMark"> — </span>Because meals may stimulate prolactin secretion slightly, if an initial serum prolactin concentration is only slightly elevated (21 to 40 ng/mL [21 to 40 mcg/L SI units]), the test should be repeated on a fasting sample before the patient is considered to have hyperprolactinemia. If serum prolactin is elevated on the second sample, hyperprolactinemia is confirmed, and the next step is to determine the cause. Most patients with hyperprolactinemia have a lactotroph adenoma. Therefore, the evaluation is aimed at (1) exclusion of pharmacologic or extrapituitary causes of hyperprolactinemia and (2) neuroradiologic evaluation of the hypothalamic-pituitary region [<a href="#rid19">19</a>]. (See  <a class="medical medical_review" href="/z/d/html/6626.html" rel="external">"Causes of hyperprolactinemia"</a>.) <span class="utd-adt-cnt utd-adt-labi">(Related Lab Interpretation Monograph(s):  <a class="narrative narrative_labi" href="/contents/high-prolactin-in-adults?topicRef=6638&amp;source=see_link">"High prolactin in adults"</a>.)</span></p><p class="headingAnchor" id="H11"><span class="h2">History</span><span class="headingEndMark"> — </span>A search for the cause of the hyperprolactinemia should begin with the history. One should inquire about pregnancy (physiologic hyperprolactinemia) and medications that can cause hyperprolactinemia (such as estrogens, neuroleptic drugs such as <a class="drug drug_general" data-topicid="9868" href="/z/d/drug information/9868.html" rel="external">risperidone</a>, <a class="drug drug_general" data-topicid="9642" href="/z/d/drug information/9642.html" rel="external">metoclopramide</a>, antidepressant drugs, <a class="drug drug_general" data-topicid="9265" href="/z/d/drug information/9265.html" rel="external">cimetidine</a>, <a class="drug drug_general" data-topicid="9635" href="/z/d/drug information/9635.html" rel="external">methyldopa</a>, and <a class="drug drug_general" data-topicid="10043" href="/z/d/drug information/10043.html" rel="external">verapamil</a>). One should also inquire about headache, visual symptoms, symptoms of hypothyroidism, and a history of renal disease.</p><p class="headingAnchor" id="H12"><span class="h2">Physical examination</span><span class="headingEndMark"> — </span>The physical examination should be directed toward testing for a chiasmal syndrome (eg, bitemporal field loss) and looking for chest wall injury and signs of hypothyroidism or hypogonadism.</p><p class="headingAnchor" id="H13"><span class="h2">Laboratory/imaging tests</span><span class="headingEndMark"> — </span>Studies should be performed to test for hypopituitarism, primary hypothyroidism, and renal insufficiency.</p><p>Magnetic resonance imaging (MRI) of the pituitary with and without contrast should be performed in a patient with any degree of hyperprolactinemia to look for a mass lesion in the hypothalamic-pituitary region, unless the patient is taking a medication known to cause hyperprolactinemia or has marked renal impairment. (See <a class="local">'Chronic kidney disease'</a> below.)</p><p>If a mass lesion is found in the region of the sella turcica, secretion of other pituitary hormones should also be evaluated. Only a pituitary adenoma can cause hypersecretion of other pituitary hormones, but any mass lesion in the area of the sella can cause hyposecretion of one or more pituitary hormones. To evaluate for hypersecretion, we suggest measurements of:</p><p class="bulletIndent1"><span class="glyph">●</span>Serum prolactin (lactotroph adenomas)</p><p class="bulletIndent1"><span class="glyph">●</span>Insulin-like growth factor-1 (IGF-1) (somatotroph adenomas)</p><p class="bulletIndent1"><span class="glyph">●</span>Plasma corticotropin (ACTH) (corticotroph adenomas)</p><p></p><p>Additional endocrine testing is needed when a gonadotroph or thyrotroph adenoma is suspected (luteinizing hormone [LH], follicle-stimulating hormone [FSH], total or free thyroxine [T4], and thyroid-stimulating hormone [TSH], respectively).</p><p>Although not generally useful in the differential diagnosis of a sellar mass, the possibility of hormonal hyposecretion should be evaluated in all patients who have a sellar mass in order to identify and replace hormone deficiencies. (See  <a class="medical medical_review" href="/z/d/html/6632.html" rel="external">"Causes, presentation, and evaluation of sellar masses", section on 'Hormonal evaluation'</a> and  <a class="medical medical_review" href="/z/d/html/6639.html" rel="external">"Diagnostic testing for hypopituitarism"</a>.)</p><p>If the MRI shows a normal hypothalamic-pituitary region and there are no obvious causes of hyperprolactinemia, the diagnosis is idiopathic hyperprolactinemia. This syndrome may, in some patients, be due to microadenomas that are too small to be seen on imaging. (See  <a class="medical medical_review" href="/z/d/html/6626.html" rel="external">"Causes of hyperprolactinemia"</a>.)</p><p class="headingAnchor" id="H438375078"><span class="h3">MRI in drug-induced hyperprolactinemia</span><span class="headingEndMark"> — </span>The degree of elevation that can be attributed to a drug depends upon the drug. Most drugs do not cause an elevation to over 100 ng/mL, but the antipsychotic drug <a class="drug drug_general" data-topicid="9868" href="/z/d/drug information/9868.html" rel="external">risperidone</a> can cause an elevation up to 300 or even 400 ng/mL [<a href="#rid20">20</a>]. Therefore, we recommend ordering magnetic resonance imaging (MRI) if the serum prolactin concentration is greater than 100 ng/mL in patients taking a drug known to elevate the prolactin concentration but greater than 300 ng/mL in those taking risperidone. There are no stimulatory or suppressive endocrine tests that distinguish between the causes of hyperprolactinemia. Similarly, the prolactin measurement need not be repeated in these patients. (See  <a class="medical medical_review" href="/z/d/html/6626.html" rel="external">"Causes of hyperprolactinemia"</a>.)</p><p class="headingAnchor" id="H4054256462"><span class="h3">Chronic kidney disease</span><span class="headingEndMark"> — </span>Hyperprolactinemia in chronic kidney disease (CKD) is due to decreased clearance of prolactin. Serum prolactin concentrations are typically elevated to as much as 10-fold normal in patients with end-stage kidney disease requiring dialysis [<a href="#rid21">21</a>]. Prolactin levels of this magnitude in the setting of end-stage kidney disease (eg, CKD 4 or 5) and in the absence of other pituitary hormone abnormalities or symptoms suggestive of pituitary tumor (eg, visual loss) typically need no further pituitary evaluation. It is unclear at which threshold of kidney dysfunction prolactin begins to rise. Therefore, in the setting of lesser degrees of renal impairment, the need for pituitary imaging is uncertain. Very mild degrees of renal impairment probably do not elevate prolactin. The decision to obtain an MRI of the pituitary is based on the magnitude of the prolactin elevation, the degree of renal impairment, and on other findings, such as visual impairment and other pituitary hormone abnormalities. MRI for a patient with any degree of renal impairment should be ordered without gadolinium.</p><p class="headingAnchor" id="H3496819659"><span class="h3">Ectopic prolactin secretion</span><span class="headingEndMark"> — </span>Secretion of prolactin from an ectopic source is uncommon but has been reported from several types of tumors [<a href="#rid22">22</a>]. An ectopic source should be suspected in a patient who has hyperprolactinemia that is not associated with a large sellar mass and is completely resistant to <a class="drug drug_general" data-topicid="8600" href="/z/d/drug information/8600.html" rel="external">cabergoline</a>.</p><p class="headingAnchor" id="H14"><span class="h1">GALACTORRHEA WITHOUT HYPERPROLACTINEMIA</span></p><p class="headingAnchor" id="H15"><span class="h2">Incidence</span><span class="headingEndMark"> — </span>The serum prolactin concentration is often normal in females who present with galactorrhea. In the largest series of patients presenting with galactorrhea, prolactin was normal in 46 percent [<a href="#rid9">9</a>]. The likelihood that the prolactin is normal is even higher if menses are normal. No cause of this phenomenon has been documented, but often it represents persistent milk secretion following resolution of a previously elevated prolactin, most commonly after nursing or drug-induced hyperprolactinemia. Galactorrhea in the absence of hyperprolactinemia is not the result of any ongoing disease. (See  <a class="medical medical_review" href="/z/d/html/802.html" rel="external">"Nipple discharge"</a>.)</p><p class="headingAnchor" id="H16"><span class="h2">Diagnosis</span><span class="headingEndMark"> — </span>The first step in diagnosis is to be sure the breast secretion is clear or milky. Green or black fluid also usually represents milk, which can be confirmed by staining the fluid for fat. Blood in the fluid is a reason for referral for evaluation of a breast tumor. If the fluid is milk, the next step is to measure the serum prolactin concentration. If the prolactin is elevated, the cause should be sought, as described above. If the prolactin is not elevated, there is no ongoing disease and no further tests are needed. Other causes of nipple discharge are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/802.html" rel="external">"Nipple discharge"</a>.)</p><p class="headingAnchor" id="H17"><span class="h2">Treatment</span><span class="headingEndMark"> — </span>Galactorrhea in the absence of hyperprolactinemia usually does not need to be treated, because it is not associated with ongoing disease and it is usually not bothersome. For the unusual patient whose galactorrhea occurs spontaneously and to a degree that causes staining of the clothes, treatment with a low dose of dopamine agonist, such as 0.25 mg of <a class="drug drug_general" data-topicid="8600" href="/z/d/drug information/8600.html" rel="external">cabergoline</a> twice a week, will reduce the prolactin concentration to below normal and reduce or eliminate the galactorrhea. (See  <a class="medical medical_review" href="/z/d/html/6630.html" rel="external">"Management of hyperprolactinemia", section on 'Initial therapy (dopamine agonists)'</a>.)</p><p class="headingAnchor" id="H1632740799"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/116386.html" rel="external">"Society guideline links: Hyperprolactinemia/prolactinoma"</a>.)</p><p class="headingAnchor" id="H1179458"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/15891.html" rel="external">"Patient education: Prolactinoma (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/z/d/html/2182.html" rel="external">"Patient education: High prolactin levels and prolactinomas (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H504478654"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical manifestations</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Premenopausal females</strong> – The clinical manifestations of hyperprolactinemia in premenopausal females are mainly those of hypogonadism. In females, these include menstrual cycle dysfunction (oligomenorrhea or amenorrhea) and infertility (luteal phase abnormalities or anovulation). Less often, galactorrhea occurs. Hyperprolactinemia accounts for approximately 10 to 20 percent of cases of amenorrhea. (See <a class="local">'Premenopausal females'</a> above.)</p><p></p><p class="bulletIndent2">The symptoms of hypogonadism due to hyperprolactinemia in premenopausal females correlate with the magnitude of the hyperprolactinemia. (See <a class="local">'Menstrual cycle dysfunction'</a> above.)</p><p></p><p class="bulletIndent2">Most premenopausal females with hyperprolactinemia do <strong>not</strong> have galactorrhea; among females who present with galactorrhea as an isolated finding, nearly 50 percent have normal serum prolactin concentrations. (See <a class="local">'Galactorrhea without hyperprolactinemia'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Postmenopausal females</strong> – Postmenopausal females are already hypogonadal, so hyperprolactinemia in them is recognized only when a lactotroph adenoma becomes large enough to cause headaches or impair vision or is detected as an incidental sellar mass by magnetic resonance imaging (MRI). In the setting of estrogen deficiency, hyperprolactinemia rarely causes galactorrhea. (See <a class="local">'Postmenopausal females'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Men</strong> – Hyperprolactinemia also causes hypogonadotropic hypogonadism in males, resulting in decreased libido and infertility. Other manifestations of hyperprolactinemia are erectile dysfunction, gynecomastia, and, rarely, galactorrhea. As in females, there is a rough correlation between the presence of any of these symptoms and the degree of hyperprolactinemia. (See <a class="local">'Males'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Prolactin</strong> – Females with oligomenorrhea, amenorrhea, or galactorrhea and males with symptoms of hypogonadism, impotence, or gynecomastia should have a serum prolactin determination. The usual normal range for serum prolactin is up to 20 ng/mL (20 mcg/L) in males and postmenopausal females and up to 30 ng/mL (30 mcg/L) in premenopausal females.</p><p></p><p class="bulletIndent2">If the prolactin concentration is only slightly high (21 to 40 ng/mL [21 to 40 mcg/L SI units]), it should be repeated before the patient is considered to have hyperprolactinemia. If the repeat value is still elevated, the next step is to determine the cause. (See  <a class="medical medical_review" href="/z/d/html/6626.html" rel="external">"Causes of hyperprolactinemia"</a>.)</p><p></p><p class="bulletIndent2">Serum prolactin values above 200 ng/mL usually indicate the presence of a lactotroph adenoma  (<a class="graphic graphic_figure graphicRef72540" href="/z/d/graphic/72540.html" rel="external">figure 1</a>). (See <a class="local">'Serum prolactin concentrations'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Pituitary MRI</strong> – MRI of the pituitary should be performed in patients with any degree of hyperprolactinemia to look for a mass lesion in the hypothalamic-pituitary region, unless the patient is taking a medication known to cause hyperprolactinemia. (See <a class="local">'Laboratory/imaging tests'</a> above.)</p><p></p><p class="bulletIndent2">We recommend ordering an MRI if the serum prolactin concentration is greater than 100 ng/mL in patients taking a drug known to elevate the prolactin concentration but greater than 300 ng/mL in those taking <a class="drug drug_general" data-topicid="9868" href="/z/d/drug information/9868.html" rel="external">risperidone</a>. (See <a class="local">'MRI in drug-induced hyperprolactinemia'</a> above.)</p><p></p><p class="bulletIndent2">If a mass lesion is found in the region of the sella turcica, secretion of other pituitary hormones should also be evaluated. Only a pituitary adenoma can cause hypersecretion of other pituitary hormones, but any mass lesion &gt;1 cm in diameter in the area of the sella can cause hyposecretion of one or more pituitary hormones. (See  <a class="medical medical_review" href="/z/d/html/6632.html" rel="external">"Causes, presentation, and evaluation of sellar masses", section on 'Hormonal evaluation'</a> and  <a class="medical medical_review" href="/z/d/html/6637.html" rel="external">"Clinical manifestations of hypopituitarism"</a>.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Gómez F, Reyes FI, Faiman C. Nonpuerperal galactorrhea and hyperprolactinemia. Clinical findings, endocrine features and therapeutic responses in 56 cases. Am J Med 1977; 62:648.</a></li><li><a class="nounderline abstract_t">Schlechte J, Sherman B, Halmi N, et al. Prolactin-secreting pituitary tumors in amenorrheic women: a comprehensive study. Endocr Rev 1980; 1:295.</a></li><li><a class="nounderline abstract_t">Bayrak A, Saadat P, Mor E, et al. Pituitary imaging is indicated for the evaluation of hyperprolactinemia. Fertil Steril 2005; 84:181.</a></li><li><a class="nounderline abstract_t">Seppälä M, Ranta T, Hirvonen E. Hyperprolactinaemia and luteal insufficiency. Lancet 1976; 1:229.</a></li><li><a class="nounderline abstract_t">Corenblum B, Pairaudeau N, Shewchuk AB. Prolactin hypersecretion and short luteal phase defects. Obstet Gynecol 1976; 47:486.</a></li><li><a class="nounderline abstract_t">Biller BM, Baum HB, Rosenthal DI, et al. Progressive trabecular osteopenia in women with hyperprolactinemic amenorrhea. J Clin Endocrinol Metab 1992; 75:692.</a></li><li><a class="nounderline abstract_t">Schlechte J, Walkner L, Kathol M. A longitudinal analysis of premenopausal bone loss in healthy women and women with hyperprolactinemia. J Clin Endocrinol Metab 1992; 75:698.</a></li><li><a class="nounderline abstract_t">Colao A, Di Somma C, Loche S, et al. Prolactinomas in adolescents: persistent bone loss after 2 years of prolactin normalization. Clin Endocrinol (Oxf) 2000; 52:319.</a></li><li><a class="nounderline abstract_t">Kleinberg DL, Noel GL, Frantz AG. Galactorrhea: a study of 235 cases, including 48 with pituitary tumors. N Engl J Med 1977; 296:589.</a></li><li><a class="nounderline abstract_t">Carter JN, Tyson JE, Tolis G, et al. Prolactin-screening tumors and hypogonadism in 22 men. N Engl J Med 1978; 299:847.</a></li><li><a class="nounderline abstract_t">Segal S, Yaffe H, Laufer N, Ben-David M. Male hyperprolactinemia:effects on fertility. Fertil Steril 1979; 32:556.</a></li><li><a class="nounderline abstract_t">Di Somma C, Colao A, Di Sarno A, et al. Bone marker and bone density responses to dopamine agonist therapy in hyperprolactinemic males. J Clin Endocrinol Metab 1998; 83:807.</a></li><li><a class="nounderline abstract_t">Melmed S, Casanueva FF, Hoffman AR, et al. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2011; 96:273.</a></li><li><a class="nounderline abstract_t">St-Jean E, Blain F, Comtois R. High prolactin levels may be missed by immunoradiometric assay in patients with macroprolactinomas. Clin Endocrinol (Oxf) 1996; 44:305.</a></li><li><a class="nounderline abstract_t">Petakov MS, Damjanović SS, Nikolić-Durović MM, et al. Pituitary adenomas secreting large amounts of prolactin may give false low values in immunoradiometric assays. The hook effect. J Endocrinol Invest 1998; 21:184.</a></li><li><a class="nounderline abstract_t">Barkan AL, Chandler WF. Giant pituitary prolactinoma with falsely low serum prolactin: the pitfall of the "high-dose hook effect": case report. Neurosurgery 1998; 42:913.</a></li><li><a class="nounderline abstract_t">Raverot V, Perrin P, Chanson P, et al. Prolactin immunoassay: does the high-dose hook effect still exist? Pituitary 2022; 25:653.</a></li><li><a class="nounderline abstract_t">Kavanagh-Wright L, Smith TP, Gibney J, McKenna TJ. Characterization of macroprolactin and assessment of markers of autoimmunity in macroprolactinaemic patients. Clin Endocrinol (Oxf) 2009; 70:599.</a></li><li><a class="nounderline abstract_t">Casanueva FF, Molitch ME, Schlechte JA, et al. Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin Endocrinol (Oxf) 2006; 65:265.</a></li><li><a class="nounderline abstract_t">David SR, Taylor CC, Kinon BJ, Breier A. The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia. Clin Ther 2000; 22:1085.</a></li><li><a class="nounderline abstract_t">Lo JC, Beck GJ, Kaysen GA, et al. Hyperprolactinemia in end-stage renal disease and effects of frequent hemodialysis. Hemodial Int 2017; 21:190.</a></li><li><a class="nounderline abstract_t">Sachdev S, Reyes MC, Snyder PJ. Ectopic Prolactin Secretion From a Uterine Leiomyoma. J Endocr Soc 2020; 4:bvaa035.</a></li></ol></div><div id="topicVersionRevision">Topic 6638 Version 35.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/558726" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Nonpuerperal galactorrhea and hyperprolactinemia. Clinical findings, endocrine features and therapeutic responses in 56 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7014211" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Prolactin-secreting pituitary tumors in amenorrheic women: a comprehensive study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16009175" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Pituitary imaging is indicated for the evaluation of hyperprolactinemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/55535" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Hyperprolactinaemia and luteal insufficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/943740" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Prolactin hypersecretion and short luteal phase defects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1517356" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Progressive trabecular osteopenia in women with hyperprolactinemic amenorrhea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1517357" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : A longitudinal analysis of premenopausal bone loss in healthy women and women with hyperprolactinemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10718830" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Prolactinomas in adolescents: persistent bone loss after 2 years of prolactin normalization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/840242" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Galactorrhea: a study of 235 cases, including 48 with pituitary tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/211411" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Prolactin-screening tumors and hypogonadism in 22 men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/499587" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Male hyperprolactinemia:effects on fertility.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9506732" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Bone marker and bone density responses to dopamine agonist therapy in hyperprolactinemic males.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21296991" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8729527" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : High prolactin levels may be missed by immunoradiometric assay in patients with macroprolactinomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9591215" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Pituitary adenomas secreting large amounts of prolactin may give false low values in immunoradiometric assays. The hook effect.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9574657" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Giant pituitary prolactinoma with falsely low serum prolactin: the pitfall of the "high-dose hook effect": case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35793045" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Prolactin immunoassay: does the high-dose hook effect still exist?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18771565" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Characterization of macroprolactin and assessment of markers of autoimmunity in macroprolactinaemic patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16886971" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11048906" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27774730" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Hyperprolactinemia in end-stage renal disease and effects of frequent hemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32296740" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Ectopic Prolactin Secretion From a Uterine Leiomyoma.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
